Base de dados : MEDLINE
Pesquisa : N03.219.521.576.215 [Categoria DeCS]
Referências encontradas : 5371 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 538 ir para página                         

  1 / 5371 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29231666
[Au] Autor:Bratlid D
[Ti] Título:Is the Norwegian System of Patient Injury Compensation in the best interests of patients?
[Ti] Título:Er pasientene tjent med Norsk pasientskadeerstatning?.
[So] Source:Tidsskr Nor Laegeforen;137(23-24), 2017 12 12.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Mh] Termos MeSH primário: Compensação e Reparação
Revisão da Utilização de Seguros/organização & administração
[Mh] Termos MeSH secundário: Competência Clínica
Seres Humanos
Imperícia/economia
Erros Médicos/economia
Erros Médicos/legislação & jurisprudência
Noruega
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.17.0340


  2 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29405686
[Au] Autor:Eramo LA
[Ti] Título:RAC Audit Underpayments: Does CMS Owe You Money?
[So] Source:J AHIMA;88(2):20-3, 2017 02.
[Is] ISSN:1060-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Auditoria Financeira
Reembolso de Seguro de Saúde
[Mh] Termos MeSH secundário: Contas a Pagar e a Receber
Centers for Medicare and Medicaid Services (U.S.)
Seres Humanos
Revisão da Utilização de Seguros
Medicare
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  3 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449892
[Au] Autor:Black J; Reaven NL; Funk SE; McGaughey K; Ohayon MM; Guilleminault C; Ruoff C
[Ad] Endereço:Stanford University, Palo Alto, CA, USA; Jazz Pharmaceuticals, Palo Alto, CA, USA. Electronic address: jedblack@stanford.edu.
[Ti] Título:Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study.
[So] Source:Sleep Med;33:13-18, 2017 May.
[Is] ISSN:1878-5506
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE/BACKGROUND: The objective of this study was to evaluate medical comorbidity patterns in patients with a narcolepsy diagnosis in the United States. PATIENTS/METHODS: This was a retrospective medical claims data analysis. Truven Health Analytics MarketScan® Research Databases were accessed to identify individuals ≥18 years of age with ≥1 diagnosis code for narcolepsy (International Classification of Diseases (ICD)-9, 347.0, 347.00, 347.01, 347.1, 347.10, or 347.11) continuously insured between 2006 and 2010, and controls without narcolepsy matched 5:1 on age, gender, region, and payer. Narcolepsy and control subjects were compared for frequency of comorbid conditions, identified by the appearance of >1 diagnosis code(s) mapped to a Clinical Classification System (CCS) level 1 category any time during the study period, and on specific subcategories, including recognized narcolepsy comorbidities of obstructive sleep apnea (OSA) and depression. RESULTS: The final study group included 9312 subjects with narcolepsy and 46,559 controls (each group: average age, 46.1 years; 59% female). As compared with controls, patients with narcolepsy showed a statistically significant excess prevalence in all the CCS multilevel categories, the only exceptions being conditions originating in the perinatal period and pregnancy/childbirth complications. The greatest excess prevalence in the narcolepsy cohort was seen for mental illness (31.1% excess prevalence; odds ratio (OR) 3.8, 95% confidence interval (CI) 3.6, 4.0), followed by diseases of the digestive system (21.4% excess prevalence; OR 2.7, 95% CI 2.5, 2.8) and nervous system/sense organs (excluding narcolepsy; 20.7% excess prevalence; OR 3.7, 95% CI 3.4, 3.9). CONCLUSIONS: In this claims analysis, a narcolepsy diagnosis was associated with a wide range of comorbid medical illness claims, at significantly higher rates than matched controls.
[Mh] Termos MeSH primário: Comorbidade/tendências
Efeitos Psicossociais da Doença
Narcolepsia/complicações
Narcolepsia/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Bases de Dados Factuais
Depressão/complicações
Depressão/epidemiologia
Feminino
Seres Humanos
Revisão da Utilização de Seguros
Masculino
Meia-Idade
Narcolepsia/epidemiologia
Polissonografia/métodos
Prevalência
Estudos Retrospectivos
Apneia Obstrutiva do Sono/complicações
Apneia Obstrutiva do Sono/epidemiologia
Apneia Obstrutiva do Sono/fisiopatologia
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  4 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779316
[Au] Autor:Kucera KL; Roos KG; Hootman JM; Lipscomb HJ; Dement JM; Silverstein BA
[Ad] Endereço:Division of Occupational & Environmental Medicine, Duke University, Durham, North Carolina.
[Ti] Título:Work-related illness and injury claims among nationally certified athletic trainers reported to Washington and California from 2001 to 2011.
[So] Source:Am J Ind Med;59(12):1156-1168, 2016 Dec.
[Is] ISSN:1097-0274
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Little is known about the work-related injury and illnesses experienced by certified athletic trainers (AT). METHODS: The incidence and characteristics of injury/illness claims filed in two workers' compensation systems were described from 2001 to 2011. Yearly populations at risk were estimated from National Athletic Trainers' Association membership statistics. Incidence rate ratios (IRR) were reported by job setting. RESULTS: Claims were predominantly for traumatic injuries and disorders (82.7%: 45.7% sprains/strains, 12.0% open wounds, 6.5% bruises) and at these body sites (back 17.2%, fingers 12.3%, and knee 9.6%) and over half were caused by body motion and overexertion (51.5%). Compared with school settings, clinic/hospital settings had modestly higher claim rates (IRR = 1.29, 95% CI: 1.06-1.52) while other settings (e.g., professional or youth sport, nursing home) had lower claim rates (IRR = 0.63, 95% CI: 0.44-0.70). CONCLUSIONS: These first known estimates of work-related injuries/illnesses among a growing healthcare profession help identify occupational tasks and settings imposing injury risk for ATs. Am. J. Ind. Med. 59:1156-1168, 2016. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Revisão da Utilização de Seguros/estatística & dados numéricos
Doenças Profissionais/epidemiologia
Traumatismos Ocupacionais/epidemiologia
Esportes/estatística & dados numéricos
Indenização aos Trabalhadores/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
California/epidemiologia
Feminino
Seres Humanos
Armazenamento e Recuperação da Informação
Masculino
Meia-Idade
Doenças Profissionais/etiologia
Traumatismos Ocupacionais/etiologia
Washington/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180124
[Lr] Data última revisão:
180124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1002/ajim.22648


  5 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29251465
[Au] Autor:Social Security Administration.
[Ti] Título:Extension of Expiration Dates for Four Body System Listings. Final rule.
[So] Source:Fed Regist;82(240):59514-5, 2017 12 15.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We are extending the expiration dates of the following body systems in the Listing of Impairments (listings) in our regulations: Musculoskeletal System, Cardiovascular System, Digestive System, and Skin Disorders. We are making no other revisions to these body systems in this final rule. This extension ensures that we will continue to have the criteria we need to evaluate impairments in the affected body systems at step three of the sequential evaluation processes for initial claims and continuing disability reviews.
[Mh] Termos MeSH primário: Avaliação da Deficiência
Definição da Elegibilidade/legislação & jurisprudência
Seguro por Invalidez/legislação & jurisprudência
Previdência Social/legislação & jurisprudência
[Mh] Termos MeSH secundário: Seres Humanos
Revisão da Utilização de Seguros/legislação & jurisprudência
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE


  6 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29232071
[Au] Autor:Employee Benefits Security Administration, Department of Labor.
[Ti] Título:Claims Procedure for Plans Providing Disability Benefits; 90-Day Delay of Applicability Date. Final rule; delay of applicability date.
[So] Source:Fed Regist;82(228):56560-6, 2017 Nov 29.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This document delays for ninety (90) days--through April 1, 2018--the applicability of a final rule amending the claims procedure requirements applicable to ERISA-covered employee benefit plans that provide disability benefits (Final Rule). The Final Rule was published in the Federal Register on December 19, 2016, became effective on January 18, 2017, and was scheduled to become applicable on January 1, 2018. The delay announced in this document is necessary to enable the Department of Labor to carefully consider comments and data as part of its effort, pursuant to Executive Order 13777, to examine regulatory alternatives that meet its objectives of ensuring the full and fair review of disability benefit claims while not imposing unnecessary costs and adverse consequences.
[Mh] Termos MeSH primário: Benefícios do Seguro/legislação & jurisprudência
Revisão da Utilização de Seguros/legislação & jurisprudência
Seguro por Invalidez/legislação & jurisprudência
[Mh] Termos MeSH secundário: Seres Humanos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE


  7 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28459735
[Au] Autor:Schulz CM; Burden A; Posner KL; Mincer SL; Steadman R; Wagner KJ; Domino KB
[Ad] Endereço:From the Department of Anesthesiology, Klinikum rechts der Isar, Technische Universität München, München, Germany (C.M.S., K.J.W.); Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Hospital, Camden, New Jersey (A.B.); Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington (K.L.P., S.L.M., K.B.D.); and Department of Anesthesiology and Perioperative Medicine, University of California Los Angeles Health System, Los Angeles, California (R.S.).
[Ti] Título:Frequency and Type of Situational Awareness Errors Contributing to Death and Brain Damage: A Closed Claims Analysis.
[So] Source:Anesthesiology;127(2):326-337, 2017 08.
[Is] ISSN:1528-1175
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Situational awareness errors may play an important role in the genesis of patient harm. The authors examined closed anesthesia malpractice claims for death or brain damage to determine the frequency and type of situational awareness errors. METHODS: Surgical and procedural anesthesia death and brain damage claims in the Anesthesia Closed Claims Project database were analyzed. Situational awareness error was defined as failure to perceive relevant clinical information, failure to comprehend the meaning of available information, or failure to project, anticipate, or plan. Patient and case characteristics, primary damaging events, and anesthesia payments in claims with situational awareness errors were compared to other death and brain damage claims from 2002 to 2013. RESULTS: Anesthesiologist situational awareness errors contributed to death or brain damage in 198 of 266 claims (74%). Respiratory system damaging events were more common in claims with situational awareness errors (56%) than other claims (21%, P < 0.001). The most common specific respiratory events in error claims were inadequate oxygenation or ventilation (24%), difficult intubation (11%), and aspiration (10%). Payments were made in 85% of situational awareness error claims compared to 46% in other claims (P = 0.001), with no significant difference in payment size. Among 198 claims with anesthesia situational awareness error, perception errors were most common (42%), whereas comprehension errors (29%) and projection errors (29%) were relatively less common. CONCLUSIONS: Situational awareness error definitions were operationalized for reliable application to real-world anesthesia cases. Situational awareness errors may have contributed to catastrophic outcomes in three quarters of recent anesthesia malpractice claims.Situational awareness errors resulting in death or brain damage remain prevalent causes of malpractice claims in the 21st century.
[Mh] Termos MeSH primário: Anestesia/efeitos adversos
Anestesia/mortalidade
Conscientização
Lesões Encefálicas/induzido quimicamente
Competência Clínica/estatística & dados numéricos
Revisão da Utilização de Seguros/estatística & dados numéricos
Imperícia/estatística & dados numéricos
[Mh] Termos MeSH secundário: Lesões Encefálicas/mortalidade
Bases de Dados Factuais/estatística & dados numéricos
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1097/ALN.0000000000001661


  8 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778316
[Au] Autor:Peterson GG; Zurovac J; Brown RS; Coburn KD; Markovich PA; Marcantonio SA; Clark WD; Mutti A; Stepanczuk C
[Ad] Endereço:Mathematica Policy Research, Washington, DC.
[Ti] Título:Testing the Replicability of a Successful Care Management Program: Results from a Randomized Trial and Likely Explanations for Why Impacts Did Not Replicate.
[So] Source:Health Serv Res;51(6):2115-2139, 2016 Dec.
[Is] ISSN:1475-6773
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To test whether a care management program could replicate its success in an earlier trial and determine likely explanations for why it did not. DATA SOURCES/SETTING: Medicare claims and nurse contact data for Medicare fee-for-service beneficiaries with chronic illnesses enrolled in the trial in eastern Pennsylvania (N = 483). STUDY DESIGN: A randomized trial with half of enrollees receiving intensive care management services and half receiving usual care. We developed and tested hypotheses for why impacts declined. DATA EXTRACTION: All outcomes and covariates were derived from claims and the nurse contact data. PRINCIPAL FINDINGS: From 2010 to 2014, the program did not reduce hospitalizations or generate Medicare savings to offset program fees that averaged $260 per beneficiary per month. These estimates are statistically different (p < .05) from the large reductions in hospitalizations and spending in the first trial (2002-2010). The treatment-control differences in the second trial disappeared because the control group's risk-adjusted hospitalization rate improved, not because the treatment group's outcomes worsened. CONCLUSION: Even if demonstrated in a randomized trial, successful results from one test may not replicate in other settings or time periods. Assessing whether gaps in care that the original program filled exist in other settings can help identify where earlier success is likely to replicate.
[Mh] Termos MeSH primário: Doença Crônica/terapia
Gerenciamento Clínico
Gastos em Saúde/estatística & dados numéricos
Hospitalização/economia
Administração dos Cuidados ao Paciente/economia
[Mh] Termos MeSH secundário: Doença Crônica/economia
Hospitalização/estatística & dados numéricos
Seres Humanos
Revisão da Utilização de Seguros
Medicare/economia
Administração dos Cuidados ao Paciente/organização & administração
Pennsylvania
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/1475-6773.12595


  9 / 5371 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28749536
[Au] Autor:Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
[Ad] Endereço:Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
[Ti] Título:The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
[So] Source:Cancer;123(22):4356-4362, 2017 Nov 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Interactions between industry and prescribers have raised concerns regarding conflicts of interest. To the best of the authors' knowledge, quantitative data measuring these interactions have been limited until recently. In the current study, the authors sought to determine whether an association exists between industry payments and prescriber behavior with regard to abiraterone and enzalutamide. METHODS: Two Centers for Medicare and Medicaid Services databases were combined to analyze oncologists and urologists who received industry payments and/or prescribed abiraterone and enzalutamide. Correlation analysis was constructed on prescription count and industry payments. Multivariable median regression examined predictors of change in prescription count per dollar of industry payment. Stratifying prescribers by quantile evaluated threshold effects on prescribers. RESULTS: The number of prescriptions was similar between prescribers who did and those who did not receive industry payment for both drugs. The median industry payment amount to prescribers differed between prescribers and nonprescribers for abiraterone ($72 vs $56) and enzalutamide ($59 vs $31). Although no statistical association was found to exist between industry payment amount and prescription count for abiraterone prescribers, an association was found to exist for enzalutamide prescribers (rho = 0.31). A small change was found with regard to prescription count per dollar of industry payment for abiraterone (0.0007 prescriptions) and enzalutamide (0.0006 prescriptions). The amount of industry payment needed to predict one additional prescription was found to be lower in the fourth and fifth quantiles compared with the first through third quantiles. CONCLUSIONS: No difference in prescription count was found to exist between prescribers who received industry payments and those who did not. A positive correlation was noted between industry payments and prescription count for enzalutamide. Ease of adoption may affect differences between the 2 drugs. Cancer 2017;123:4356-62. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Androstenos/economia
Androstenos/uso terapêutico
Indústria Farmacêutica/economia
Medicare/economia
Feniltioidantoína/análogos & derivados
Padrões de Prática Médica/economia
[Mh] Termos MeSH secundário: Conflito de Interesses
Custos de Medicamentos
Indústria Farmacêutica/ética
Ética Médica
Gastos em Saúde/estatística & dados numéricos
Seres Humanos
Revisão da Utilização de Seguros
Medicare/estatística & dados numéricos
Feniltioidantoína/economia
Feniltioidantoína/uso terapêutico
Médicos/economia
Médicos/ética
Padrões de Prática Médica/ética
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstenes); 0 (MDV 3100); 2010-15-3 (Phenylthiohydantoin); G819A456D0 (abiraterone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30914


  10 / 5371 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460994
[Au] Autor:Chappidi MR; Kates M; Sopko NA; Joice GA; Tosoian JJ; Pierorazio PM; Bivalacqua TJ
[Ad] Endereço:The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: mchappi1@jhmi.edu.
[Ti] Título:Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database.
[So] Source:J Sex Med;14(6):810-817, 2017 Jun.
[Is] ISSN:1743-6109
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: To improve care for patients after radical cystoprostatectomy (RCP), focus on survivorship issues such as sexual function needs to increase. Previous studies have demonstrated the burden of erectile dysfunction (ED) after RCP to be as high as 89%. AIM: To determine the rates of ED treatment use (phosphodiesterase type 5 inhibitors, injectable therapies, urethral suppositories, vacuum erection devices, and penile prosthetics) in patients with bladder cancer before and after RCP to better understand current patterns of care. METHODS: Men with bladder cancer undergoing RCP were identified in the MarketScan database (2010-2014). ED treatment use was assessed at baseline (during the 1 year before RCP) and at 6-month intervals (0-6, 7-12, 13-18, 19-24 months) after RCP. Multivariable logistic regression models were used to identify predictors of ED treatment use at 6-month intervals after RCP. OUTCOMES: ED treatment rates and predictors of ED treatment at 0-6, 7-12, 13-18, 19-24 month follow-up after RCP. RESULTS: At baseline, 6.5% of patients (77 of 1,176) used ED treatments. The rates of ED treatment use at 0 to 6, 7 to 12, 13 to 18, and 19 to 24 months after RCP were 15.2%, 12.7%, 8.1%, and 10.1% respectively. Phosphodiesterase type 5 inhibitors were the most commonly used treatment at all time points. In the multivariable model, predictors of ED treatment use at 0 to 6 months after RCP were age younger than 50 years (odds ratio [OR] = 3.17, 95% CI = 1.68-6.01), baseline ED treatment use (OR = 5.75, 95% CI = 3.08-10.72), neoadjuvant chemotherapy (OR = 1.72, 95% CI = 1.13-2.61), and neobladder diversion (OR = 2.40, 95% CI = 1.56-3.70). Baseline ED treatment use continued to be associated with ED treatment use at 6 to 12 months (OR = 5.63, 95% CI = 2.42-13.10) and 13 to 18 months (OR = 8.99, 95% CI = 3.05-26.51) after RCP. CLINICAL IMPLICATIONS: While the burden of ED following RCP is known to be high, overall ED treatment rates are low. These findings suggest either ED treatment is low priority for RCP patients or education about potential ED therapies may not be commonly discussed with patients following RCP. Urologists should consider discussing sexual function more frequently with their RCP patients. STRENGTHS & LIMITATIONS: Strengths include the use of a national claims database, which allows for longitudinal follow-up and detailed information on prescription medications and devices. Limitations include the lack of pathologic and oncologic outcomes data. CONCLUSION: ED treatment use after RCP is quite low. The strongest predictor of ED treatment use after RCP was baseline treatment use. These findings suggest ED treatment is a low priority for patients with RCP or education about potential ED therapies might not be commonly discussed with patients after RCP. Urologists should consider discussing sexual function more frequently with their patients undergoing RCP. Chappadi MR, Kates M, Sopko NA, et al. Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database. J Sex Med 2017;14:810-817.
[Mh] Termos MeSH primário: Cistectomia/efeitos adversos
Disfunção Erétil/etiologia
Disfunção Erétil/terapia
Revisão da Utilização de Seguros/estatística & dados numéricos
Prostatectomia/efeitos adversos
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Cistectomia/métodos
Seres Humanos
Masculino
Meia-Idade
Inibidores da Fosfodiesterase 5/uso terapêutico
Prostatectomia/métodos
Fatores de Tempo
Neoplasias da Bexiga Urinária/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phosphodiesterase 5 Inhibitors)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE



página 1 de 538 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde